Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Technology Stocks & Market Talk With Don Wolanchuk -- Ignore unavailable to you. Want to Upgrade?

To: Investor2 who wrote (160200)	9/4/2021 9:10:46 PM
From: Winfastorlose	5 Recommendations Recommended By DrO Hugh Bett Mick Mørmøny roguedolphin vixson Read Replies (1) \| Respond to of 207841

I believe he was referring to the past. Don't know if you listened to him or not, but it was highly informational This "approval" is totally unique. It was made with no long term safety study completed No public hearing and no evidence presented to the public. It was done behind closed doors. There were also two letters written. One to BioNTech, one to Pfizer. The Pfizer letter extended the EUA, the BioNtech letter approved the drug "Cominarty", which has yet to be produced under that label here. So in the meantime, PFE will enjoy protection from liability that a producer gets from an EUA. Personally, I would say this approval is somewhat of a rigged scam.